Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

Inclusion Criteria: * Body Mass index (BMI) of at least 30 kg/m² or BMI \>27 kg/m² with associated risk factors such as type 2 diabetes or dyslipidemia Exclusion Criteria: * Weight loss \> 5 kg within 3 months prior to screening Visit. * Presence of any clinically significant endocrine disease including the presence of type 1 diabetes * Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders * Previous participation in a clinical study with rimonabant * Administration of other investigational drugs, anti-obesity drugs or other drugs for weight reduction * Pregnancy and absence of effective contraceptive method for females of childbearing potential * Exenatide * Insulin therapy * Recent change or need for change in the oral antidiabetic treatment * Recent change or need for change in the lipid lowering treatment * Presence of severe renal or hepatic impairment The above information is not intented to contain all considerations relevant to a patient's potential participation in a clinical trial.